



## Drug Candidates Target HTLV-1 and HTLV-1-Related Diseases

Guest Editors:

**Dr. Juliana Echevarria Neves de Lima**

Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, Brazil

[juechevarria@micro.ufrj.br](mailto:juechevarria@micro.ufrj.br)

**Dr. Goedele N. Maertens**

Faculty of Medicine, Department of Infectious Disease, Imperial College London, London, UK

[g.maertens@imperial.ac.uk](mailto:g.maertens@imperial.ac.uk)

Deadline for manuscript submissions:

**30 June 2023**

### Message from the Guest Editors

Estimates indicate that more than 10 million individuals live with human T-cell lymphotropic virus type 1 (HTLV-1) worldwide. HTLV-1 is a retrovirus responsible for highly aggressive neoplastic diseases, such as adult T-cell leukemia/Lymphoma (ATLL), and inflammatory diseases as HTLV-1-associated myelopathic/tropical spastic paraparesis (HAM/TSP). Despite the advances in understanding the pathogenesis of HTLV-1, there is still a need to develop more effective therapies. ATLL carriers have a poor prognosis for disease evolution and a low life expectancy. These patients usually receive combined chemotherapy, but the infected cells are resistant to a large part of the cell death-inducing agents. Moreover, asymptomatic people living with HTLV-1 or carriers of HTLV-1-related diseases are treated against some symptoms using corticosteroids. However, some new compounds or drug repositioning and immunotherapy have been described with treatment promising for HTLV-1-related disease. In addition, there is promise to use antiretrovirals as a pre-exposure prophylaxis. The aim of this Special Issue is to compile the new findings in this area.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:**— free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** [JCR - Q1 \(Pharmacology & Pharmacy\)](#) / [CiteScore - Q2 \(Pharmaceutical Science\)](#)

## Contact Us

*Pharmaceuticals*  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)